Background and Aims: Most cases of infective endocarditis are caused by nonenterococcal streptococci. The emergence of strains resistant to penicillin is increasingly recognized worldwide. This study sought to assess the effect of penicillin resistance on presentation and outcome of streptococcal endocarditis. Methods: A retrospective study was conducted in a single tertiary care hospital. Results: Between August 1996 and December 2004, patients infected with nonenterococcal streptococcal endocarditis and known minimal inhibitory concentrations (MICs) to penicillin were included in this study. A total of 62 cases were identified: 48 (77%) cases of the streptococcal endocarditis were caused by viridans streptococci. The most common species groups identified were Streptococcus mitis in 12 (19%) cases, Streptococcus oralis in 9 (15%) cases, Streptococcus sanguis in 7 (11%) cases and Streptococcus mutans in 7 (11%) cases. There were 36 male and 26 female patients with a median age of 46 years (range: 1–85). Twenty-two patients (35%) had peripheral embolization and 10 patients (16%) died in hospital. Twenty-eight (45%) of the 62 patients were infected with streptococcal strains of MICs ≧0.125 µg/ml to penicillin. Infection with streptococcal strains of MICs ≧0.125 µg/ml to penicillin was associated with a lower incidence of all-site embolization, but was not associated with higher mortality or increased frequency of surgery. Conclusions: High-level penicillin resistance of the streptococci responsible for endocarditis was increasingly common and medical therapy with vancomycin had a good response. Penicillin resistance was associated with a decreased risk of embolization, but was not associated with higher mortality.

Keywords:
Streptococcus, Infective endocarditis, Penicillin resistance, Embolization
1.
Netzer RO, Altwegg SC, Zollinger E, Tauber M, Carrel T, Seiler C: Infective endocarditis: determinants of long term outcome. Heart 2002;88:61–66.
2.
Bouza E, Menasalvas A, Munoz P, Vasallo FJ, del Mar Moreno M, Garcia Fernandez MA: Infective endocarditis – a prospective study at the end of the twentieth century: new predisposing conditions, new etiologic agents, and still a high mortality. Medicine 2001;80:298–307.
3.
Hoen B, Alla F, Selton-Suty C, Beguinot I, Bouvet A, Briancon S, Casalta JP, Danchin N, Delahaye F, Etienne J, Le Moing V, Leport C, Mainardi JL, Ruimy R, Vandenesch F; Association pour l’Etude et la Prévention de l’Endocardite Infectieuse (AEPEI) Study Group: Changing profile of infective endocarditis: results of a 1-year survey in France. JAMA 2002;288:75–81.
4.
DiNubile MJ: Treatment of endocarditis caused by relatively resistant nonenterococcal streptococci: is penicillin enough? Rev Infect Dis 1990;12:112–117.
5.
Prabhu RM, Piper KE, Baddour LM, Steckelberg JM, Wilson WR, Patel R: Antimicrobial susceptibility patterns among viridans group streptococcal isolates from infective endocarditis patients from 1971 to 1986 and 1994 to 2002. Antimicrob Agents Chemother 2004;48:4463–4465.
6.
Levy CS, Kogulan P, Gill VJ, Croxton MB, Kane JG, Lucey DR: Endocarditis caused by penicillin-resistant viridans streptococci: 2 cases and controversies in therapy. Clin Infect Dis 2001;33:577–579.
7.
Siegel M, Timpone J: Penicillin-resistant Streptococcus pneumoniae endocarditis: a case report and review. Clin Infect Dis 2001;32:972–974.
8.
Lonks JR, Dickinson BP, Runarsdottir V: Endocarditis due to Streptococcus mitis with high-level resistance to penicillin and cefotaxime. N Engl J Med 1999;341:1239.
9.
Hanslik T, Hartig C, Jurand C, Armand-Lefevre L, Jubault V, Rouveix E, Dubourg O, Prinseau J, Baglin A, Nicolas-Chanoine MH: Clinical significance of tolerant strains of streptococci in adults with infective endocarditis. Clin Microbiol Infect 2003;9:852–857.
10.
Martinez E, Miro JM, Almirante B, Aguado JM, Fernandez-Viladrich P, Fernandez-Guerrero ML, Villanueva JL, Dronda F, Moreno-Torrico A, Montejo M, Llinares P, Gatell JM; Spanish Pneumococcal Endocarditis Study Group: Effect of penicillin resistance of Streptococcus pneumoniae on the presentation, prognosis, and treatment of pneumococcal endocarditis in adults. Clin Infect Dis 2002;35:130–139.
11.
Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG Jr, Ryan T, Bashore T, Corey GR: Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 2000;30:633–638.
12.
Beighton D, Hardie JM, Whiley RA: A scheme for the identification of viridans streptococci. J Med Microbiol 1991;35:367–372.
13.
National Committee for Clinical Laboratory Standards: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Approved Standard, ed 4. Document M7-A4. Wayne, National Committee for Clinical Laboratory Standards, 1997.
14.
Hoen B: Special issues in the management of infective endocarditis caused by gram-positive cocci. Infect Dis Clin North Am 2002;16:437–452.
15.
Jones RN, Wilson WR: Epidemiology, laboratory detection, and therapy of penicillin-resistant streptococcal infections. Diagn Microbiol Infect Dis 1998;31:453–459.
16.
Hsueh PR, Teng LJ, Wu TL, Yang D, Huang WK, Shyr JM, Chuang YC, Wan JH, Yan JJ, Lu JJ, Wu JJ, Ko WC, Chang FY, Yang YC, Lau YJ, Liu YC, Lee CM, Leu HS, Liu CY, Luh KT; SMART Program 2001 Data: Telithromycin- and fluoroquinolone-resistant Streptococcus pneumoniae in Taiwan with high prevalence of resistance to macrolides and beta-lactams: SMART program 2001 data. Antimicrob Agents Chemother 2003;47:2145–2151.
17.
Song JH, Jung SI, Ko KS, Kim NY, Son JS, Chang HH, Ki HK, Oh WS, Suh JY, Peck KR, Lee NY, Yang Y, Lu Q, Chongthaleong A, Chiu CH, Lalitha MK, Perera J, Yee TT, Kumarasinghe G, Jamal F, Kamarulzaman A, Parasakthi N, Van PH, Carlos C, So T, Ng TK, Shibl A: High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study). Antimicrob Agents Chemother 2004;48:2101–2107.
18.
Millaire A, Leroy O, Gaday V, de Groote P, Beuscart C, Goullard L, Beaucaire G, Ducloux G: Incidence and prognosis of embolic events and metastatic infections in infective endocarditis. Eur Heart J 1997;18:677–684.
19.
Deprele C, Berthelot P, Lemetayer F, Comtet C, Fresard A, Cazorla C, Fascia P, Cathebras P, Chaumentin G, Convert G, Isaaz K, Barral X, Lucht F: Risk factors for systemic emboli in infective endocarditis. Clin Microbiol Infect 2004;10:46–53.
20.
Vilacosta I, Graupner C, San Roman JA, Sarria C, Ronderos R, Fernandez C, Mancini L, Sanz O, Sanmartin JV, Stoermann W: Risk of embolization after institution of antibiotic therapy for infective endocarditis. J Am Coll Cardiol 2002;39:1489–1495.
21.
Ringberg H, Thoren A, Lilija B: Metastatic complications of Staphylococcus aureus septicemia. To seek is to find. Infection 2000;28:132–136.
22.
Lefort A, Mainardi JL, Selton-Suty C, Casassus P, Guillevin L, Lortholary O: Streptococcus pneumoniae endocarditis in adults. A multicenter study in France in the era of penicillin resistance (1991–1998). The Pneumococcal Endocarditis Study Group. Medicine 2000;79:327–337.
23.
Aronin SI, Mukherjee SK, West JC, Cooney EL: Review of pneumococcal endocarditis in adults in the penicillin era. Clin Infect Dis 1998;26:165–171.
24.
Travers K, Barza M: Morbidity of infections caused by antimicrobial-resistant bacteria. Clin Infect Dis 2002;34:S131–S134.
25.
Hsu RB, Chu SH: Impact of methicillin resistance on clinical features and outcomes of infective endocarditis due to Staphylococcus aureus. Am J Med Sci 2004;328:150–155.
26.
Vaudaux PE, Monzillo V, Francois P, Lew DP, Foster TJ, Berger-Bachi B: Introduction of the mec element (methicillin resistance) into Staphylococcus aureus alters in vitro functional activities of fibrinogen and fibronectin adhesions. Antimicrob Agents Chemother 1998;42:564–570.
27.
Teng LJ, Hsueh PR, Chen YC, Ho SW, Luh KT: Antimicrobial susceptibility of viridans group streptococci in Taiwan with an emphasis on the high rates of resistance to penicillin and macrolides in Streptococcus oralis. J Antimicrob Chemother 1998;41:621–627.
28.
Garcia-Bustos J, Tomasz A: A biological price of antibiotic resistance: major changes in the peptidoglycan structure of penicillin-resistant pneumococci. Proc Natl Acad Sci USA 1990;87:5415–5419.
29.
Smith A, Jackson MS, Kennedy H: Antimicrobial susceptibility of viridans group streptococcal blood isolates to eight antimicrobial agents. Scand J Infect Dis 2004;36:259–263.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.